Meeting Report

2018–2019 Drug Updates in Hematologic Malignancies

Presented by Lauren Held, PharmD, BCOP

From Seattle Cancer Care Alliance, Seattle, Washington

Presenter’s disclosure of conflicts of interest is found at the end of this article.


J Adv Pract Oncol 2020;11(3):249–253 | https://doi.org/10.6004/jadpro.2020.11.3.7 | © 2020 Harborside™


  

ABSTRACT

Lauren Held, PharmD, BCOP, updated attendees on the FDA-approved therapies for initial or expanded indications for hematologic malignancies across the past year, as well as their supporting clinical trial data and best practices for safe and effective dosing and administration, drug monitoring, and adverse event management. 




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.